- Home
- YOUL vs QNCX Comparison
YOUL vs QNCX Comparison
Compare YOUL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YOUL | QNCX |
|---|---|---|
| Founded | N/A | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.6M | 139.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | YOUL | QNCX |
|---|---|---|
| Price | $1.52 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | N/A | ★ 943.8K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.72 |
| 52 Week High | N/A | $4.55 |
Technical Indicators
Market Signals| Indicator | YOUL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.80 |
| Support Level | N/A | $3.44 |
| Resistance Level | N/A | $3.80 |
| Average True Range (ATR) | 0.00 | 0.34 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 17.77 |
Price Performance
Historical ComparisonAbout YOUL Youlife Group Inc. American Depositary Shares
Youlife Group Inc is a blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.